Elevate Now Nets ₹18 Cr To Help Users Shed Weight

The startup plans to utilise the fresh funding to strengthen its tech stack, develop nutritional supplements and expand its proprietary clinical research

Founded in 2022, ElevateNow offers personalised support, therapies, and guidance on nutrition, fitness, and stress management

The fundraise comes amid growing global interest in weight loss companies as GLP-1 drugs like Ozempic and Mounjaro sweep the market

Healthtech startup Elevate Now has raised ₹18 Cr (nearly $2 Mn) in its seed funding round led by Physis Capital. The round also saw participation from Inflection Point Ventures and Titan Capital.

The startup plans to utilise the fresh funding to strengthen its tech stack and develop nutritional supplements. In a statement, Elevate Now also said that a chunk of the capital will be used to expand its proprietary clinical research and build personalisation systems to improve outcomes at scale.

“What stood out to us was the company’s ability to combine clinical-grade outcomes with a consumer-first experience. Elevate Now is building a scalable business by applying operational rigour to a problem that has traditionally lacked structure,” said a Titan Capital spokesperson. 

Founded in 2022 by ex-Swiggy executive Suryansh Kumar, ElevateNow offers online weight management programmes. The subscription-led platform claims to offer personalised support, therapies, and guidance on nutrition, fitness, and stress management. It also claims to offer glucagon-like peptide-1 (GLP-1) drugs for medically-assisted weight loss. 

The Bengaluru-based startup claims to have onboarded more than 30,000 paid users so far The company claims to have clocked an average month-on-month revenue growth rate of 17% between April 2025 and January 2026, without disclosing actual numbers. 

Prior to the current round, Elevate Now had raised $1.8 Mn from the likes of W Health Ventures, Narayana Health, and Swiggy cofounder Sriharsha Majety.

The fundraise comes amid growing global interest in weight loss companies as GLP-1 drugs like Ozempic and Mounjaro sweep the market. The diabetes drugs have quickly gained market share for their effectiveness in weight loss. 

Back home, startups like Healthify and HealthifyRx are also working on similar products that help users shed weight in a short span. And there is a hefty local target market for such offerings too. As per a  Lancet study, an estimated 218 Mn men and 232 Mn women will be overweight or obese in India by 2050. 

On the back of this, reports estimate that the homegrown anti-obesity drugs market is projected to become a $100 Bn opportunity by 2030.